Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Novo Nordisk to Acquire Cardior in €1.025B Acquisition

Mar 25, 2024

On 25 Mar 2024, Novo Nordisk announced the acquisition of Cardior Pharmaceuticals for (up to) € 1.025B comprised of an initial payment and milestone payments.

Cardior Pharmaceuticals specialises in RNA-targeted therapies aimed at preventing, repairing, and reversing heart diseases.  Its lead compound, CDR132L, reportedly selectively blocks abnormal levels of miR-132.  Phase 1b trial results showed promising safety and tolerability along with promising cardiac functional improvements in heart failure patients.  As reported in Novo Nordisk’s press release, the ongoing phase 2 trials aim to benefit individuals with heart failure with reduced ejection fraction (HFrEF) who have previously experienced a heart attack.

The Novo Nordisk press release states that it plans to initiate a second phase 2 trial to investigate CDR132L in a chronic heart failure population with cardiac hypertrophy.

The acquisition is expected to be finalised in the second quarter of 2024, subject to regulatory approvals.

This news follows the 5 February 2024 announcement by Novo Holdings (Novo Nordisk’s parent company) that it acquired global contract development and manufacturing company Catalent for USD $16.5B, a deal which is expected to close in late 2024.